We are analyzing https://link.springer.com/article/10.1007/s00018-019-03084-7.

Title:
The role of ASXL1 in hematopoiesis and myeloid malignancies | Cellular and Molecular Life Sciences
Description:
Recent high-throughput genome-wide sequencing studies have identified recurrent somatic mutations in myeloid neoplasms. An epigenetic regulator, Additional sex combs-like 1 (ASXL1), is one of the most frequently mutated genes in all subtypes of myeloid malignancies. ASXL1 mutations are also frequently detected in clonal hematopoiesis, which is associated with an increased risk of mortality. Therefore, it is important to understand how ASXL1 mutations contribute to clonal expansion and myeloid transformation in hematopoietic cells. Studies using ASXL1-depleted human hematopoietic cells and Asxl1 knockout mice have shown that deletion of wild-type ASXL1 protein leads to impaired hematopoiesis and accelerates myeloid malignancies via loss of interaction with polycomb repressive complex 2 proteins. On the other hand, ASXL1 mutations in myeloid neoplasms typically occur near the last exon and result in the expression of C-terminally truncated mutant ASXL1 protein. Biological studies and biochemical analyses of this variant have shed light on its dominant-negative and gain-of-function features in myeloid transformation via a variety of epigenetic changes. Based on these results, it would be possible to establish novel promising therapeutic strategies for myeloid malignancies harboring ASXL1 mutations by blocking interactions between ASXL1 and associating epigenetic regulators. Here, we summarize the clinical implications of ASXL1 mutations, the role of wild-type ASXL1 in normal hematopoiesis, and oncogenic functions of mutant ASXL1 in myeloid neoplasms.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Business & Finance
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, article, google, scholar, cas, asxl, mutations, central, myeloid, leukemia, cell, hematopoiesis, blood, gene, acute, myelodysplastic, patients, clinical, chronic, tet, nat, malignancies, neoplasms, additional, clonal, syndromes, myelomonocytic, zhang, med, sex, prognostic, wang, inoue, bap, histone, leukaemia, cancer, genet, hematol, chen, research, role, somatic, loss, polycomb, mutation, engl, oncol, idh, genetic,

Topics {✒️}

month download article/chapter susumu goyama & toshio kitamura acute myeloid leukaemia malignant myeloid diseases vega-rubin-de-celis chronic myelomonocytic leukaemia prc2-mediated gene repression /runx1-runx1t1 chromosomal translocations full article pdf age-related clonal hematopoiesis micol jb hox gene silencing e2f1-responsive gene expression accelerate myeloid malignancy mast-cell diseases abdel-wahab therapy-related clonal hematopoiesis blast-phase myeloproliferative neoplasms blood-cancer risk inferred exome sequencing reveals bohring-opitz syndrome acute myeloid leukemia post-polycythemia vera myelofibrosis drosophila hox genes myelodysplastic syndrome patients acute myeloid leukemias promote myeloid leukaemogenesis article asada mds/mpn aid scientific research asxl1-mutated mds privacy choices/manage cookies accelerates myeloid malignancies high-risk group lin cc malignant pleural mesothelioma wild-type asxl1 asxl1 truncating protein chronic myelomonocytic leukemia asxl1–bap1 complex nuclear deubiquitinase bap1 additional sex combs additional sex combs chronic myelogenous leukemia bmc cancer 10 detectable protein levels advanced systemic mastocytosis article cellular tumor suppressor bap1 myelodysplastic syndrome

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The role of ASXL1 in hematopoiesis and myeloid malignancies
         description:Recent high-throughput genome-wide sequencing studies have identified recurrent somatic mutations in myeloid neoplasms. An epigenetic regulator, Additional sex combs-like 1 (ASXL1), is one of the most frequently mutated genes in all subtypes of myeloid malignancies. ASXL1 mutations are also frequently detected in clonal hematopoiesis, which is associated with an increased risk of mortality. Therefore, it is important to understand how ASXL1 mutations contribute to clonal expansion and myeloid transformation in hematopoietic cells. Studies using ASXL1-depleted human hematopoietic cells and Asxl1 knockout mice have shown that deletion of wild-type ASXL1 protein leads to impaired hematopoiesis and accelerates myeloid malignancies via loss of interaction with polycomb repressive complex 2 proteins. On the other hand, ASXL1 mutations in myeloid neoplasms typically occur near the last exon and result in the expression of C-terminally truncated mutant ASXL1 protein. Biological studies and biochemical analyses of this variant have shed light on its dominant-negative and gain-of-function features in myeloid transformation via a variety of epigenetic changes. Based on these results, it would be possible to establish novel promising therapeutic strategies for myeloid malignancies harboring ASXL1 mutations by blocking interactions between ASXL1 and associating epigenetic regulators. Here, we summarize the clinical implications of ASXL1 mutations, the role of wild-type ASXL1 in normal hematopoiesis, and oncogenic functions of mutant ASXL1 in myeloid neoplasms.
         datePublished:2019-03-30T00:00:00Z
         dateModified:2019-03-30T00:00:00Z
         pageStart:2511
         pageEnd:2523
         sameAs:https://doi.org/10.1007/s00018-019-03084-7
         keywords:
            ASXL1
            BAP1
            HOX
            Acute myeloid leukemia
            AML
            Myelodysplastic syndrome
            MDS
            MPN
            CMML
            Cell Biology
            Biomedicine
            general
            Life Sciences
            Biochemistry
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-019-03084-7/MediaObjects/18_2019_3084_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-019-03084-7/MediaObjects/18_2019_3084_Fig2_HTML.png
         isPartOf:
            name:Cellular and Molecular Life Sciences
            issn:
               1420-9071
               1420-682X
            volumeNumber:76
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Shuhei Asada
               affiliation:
                     name:The University of Tokyo
                     address:
                        name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Takeshi Fujino
               affiliation:
                     name:The University of Tokyo
                     address:
                        name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Susumu Goyama
               affiliation:
                     name:The University of Tokyo
                     address:
                        name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Toshio Kitamura
               affiliation:
                     name:The University of Tokyo
                     address:
                        name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The role of ASXL1 in hematopoiesis and myeloid malignancies
      description:Recent high-throughput genome-wide sequencing studies have identified recurrent somatic mutations in myeloid neoplasms. An epigenetic regulator, Additional sex combs-like 1 (ASXL1), is one of the most frequently mutated genes in all subtypes of myeloid malignancies. ASXL1 mutations are also frequently detected in clonal hematopoiesis, which is associated with an increased risk of mortality. Therefore, it is important to understand how ASXL1 mutations contribute to clonal expansion and myeloid transformation in hematopoietic cells. Studies using ASXL1-depleted human hematopoietic cells and Asxl1 knockout mice have shown that deletion of wild-type ASXL1 protein leads to impaired hematopoiesis and accelerates myeloid malignancies via loss of interaction with polycomb repressive complex 2 proteins. On the other hand, ASXL1 mutations in myeloid neoplasms typically occur near the last exon and result in the expression of C-terminally truncated mutant ASXL1 protein. Biological studies and biochemical analyses of this variant have shed light on its dominant-negative and gain-of-function features in myeloid transformation via a variety of epigenetic changes. Based on these results, it would be possible to establish novel promising therapeutic strategies for myeloid malignancies harboring ASXL1 mutations by blocking interactions between ASXL1 and associating epigenetic regulators. Here, we summarize the clinical implications of ASXL1 mutations, the role of wild-type ASXL1 in normal hematopoiesis, and oncogenic functions of mutant ASXL1 in myeloid neoplasms.
      datePublished:2019-03-30T00:00:00Z
      dateModified:2019-03-30T00:00:00Z
      pageStart:2511
      pageEnd:2523
      sameAs:https://doi.org/10.1007/s00018-019-03084-7
      keywords:
         ASXL1
         BAP1
         HOX
         Acute myeloid leukemia
         AML
         Myelodysplastic syndrome
         MDS
         MPN
         CMML
         Cell Biology
         Biomedicine
         general
         Life Sciences
         Biochemistry
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-019-03084-7/MediaObjects/18_2019_3084_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00018-019-03084-7/MediaObjects/18_2019_3084_Fig2_HTML.png
      isPartOf:
         name:Cellular and Molecular Life Sciences
         issn:
            1420-9071
            1420-682X
         volumeNumber:76
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shuhei Asada
            affiliation:
                  name:The University of Tokyo
                  address:
                     name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Takeshi Fujino
            affiliation:
                  name:The University of Tokyo
                  address:
                     name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Susumu Goyama
            affiliation:
                  name:The University of Tokyo
                  address:
                     name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Toshio Kitamura
            affiliation:
                  name:The University of Tokyo
                  address:
                     name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cellular and Molecular Life Sciences
      issn:
         1420-9071
         1420-682X
      volumeNumber:76
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The University of Tokyo
      address:
         name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
         type:PostalAddress
      name:The University of Tokyo
      address:
         name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
         type:PostalAddress
      name:The University of Tokyo
      address:
         name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
         type:PostalAddress
      name:The University of Tokyo
      address:
         name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shuhei Asada
      affiliation:
            name:The University of Tokyo
            address:
               name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
               type:PostalAddress
            type:Organization
      name:Takeshi Fujino
      affiliation:
            name:The University of Tokyo
            address:
               name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
               type:PostalAddress
            type:Organization
      name:Susumu Goyama
      affiliation:
            name:The University of Tokyo
            address:
               name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
               type:PostalAddress
            type:Organization
      name:Toshio Kitamura
      affiliation:
            name:The University of Tokyo
            address:
               name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
      name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
      name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
      name:Division of Cellular Therapy, Advanced Clinical Research Center, and Division of Stem Cell Signaling, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(448)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.25s.

LINK . SPRINGER . COM {}